SEOM clinical guidelines for pancreatic and biliary tract cancer (2020).
Albumins
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biliary Tract Neoplasms
/ genetics
Capecitabine
/ therapeutic use
Chemoradiotherapy
/ methods
Chemotherapy, Adjuvant
/ methods
Cisplatin
/ therapeutic use
Fluorouracil
/ therapeutic use
Humans
Irinotecan
/ therapeutic use
Leucovorin
/ therapeutic use
Medical Oncology
Neoadjuvant Therapy
/ methods
Neoplasm Staging
Oxaliplatin
/ therapeutic use
Paclitaxel
/ therapeutic use
Palliative Care
Pancreatic Neoplasms
/ genetics
Quality of Life
Societies, Medical
Spain
Biliary tract cancer
Chemotherapy
Pancreatic cancer
Radiotherapy
Treatment
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
accepted:
10
02
2021
pubmed:
5
3
2021
medline:
31
8
2021
entrez:
4
3
2021
Statut:
ppublish
Résumé
Pancreatic cancer (PC) and biliary tract cancer (BTC) are both aggressive and highly fatal malignancies. Nowadays we have a profound knowledge about the molecular landscape of these neoplasms and this has allowed new therapeutic options. Surgery is the only potentially curative therapy in both cancers, but disease recurrence is frequent. In PC, adjuvant treatment with mFOLFIRINOX has improved overall survival (OS) and in BTC adjuvant treatment with capecitabine seems to improve OS and relapse-free survival. Concomitant radio-chemotherapy could also be considered following R1 surgery in both neoplasms. Neoadjuvant treatment represents the best option for achieving an R0 resection in borderline PC. Upfront systemic chemotherapy is the treatment of choice in unresectable locally advanced PC and BTC; then locoregional therapy could be considered after an initial period of at least 3-4 months of systemic chemotherapy. In metastatic PC, FOLFIRINOX or Gemcitabine plus nab-paclitaxel have improved OS compared with gemcitabine alone. In metastatic BTC, cisplatin plus gemcitabine constitute the standard treatment. Progress in the knowledge of molecular biology has enabled the identification of new targets for therapy with encouraging results that could in the future improve the survival and quality of life of patients with PC and BTC.
Identifiants
pubmed: 33660222
doi: 10.1007/s12094-021-02573-1
pii: 10.1007/s12094-021-02573-1
pmc: PMC8058005
doi:
Substances chimiques
130-nm albumin-bound paclitaxel
0
Albumins
0
folfirinox
0
Oxaliplatin
04ZR38536J
Capecitabine
6804DJ8Z9U
Irinotecan
7673326042
Paclitaxel
P88XT4IS4D
Cisplatin
Q20Q21Q62J
Leucovorin
Q573I9DVLP
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
988-1000Références
GBD 2017. Pancreatic cancer collaborators. The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2019;4:934–47. https://doi.org/10.1016/S2468-1253(19)30347-4 .
doi: 10.1016/S2468-1253(19)30347-4
Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–61. https://doi.org/10.1016/j.cell.2011.11.025 .
doi: 10.1016/j.cell.2011.11.025
pubmed: 22265420
pmcid: 3266542
Collison EA, Bailey P, Chang DK, et al. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019;16(4):207–20. https://doi.org/10.1038/s41575-0190109-y .
doi: 10.1038/s41575-0190109-y
O’Kane GM, Grünwald BT, Jang GH, et al. GATA6 expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer. Clin Can Res. 2020. https://doi.org/10.1158/1078-0432.CCR-19-3724 .
doi: 10.1158/1078-0432.CCR-19-3724
Zao SG, Chen WS, Das R, et al. Clinical and genomic implications of luminal and basal subtypes across carcinomas. Clin Can Res. 2019;25(8):2450–7. https://doi.org/10.1158/1078-0432.CCR-18-3121 .
doi: 10.1158/1078-0432.CCR-18-3121
Capello M, Fahrmann JF, Rios Perez MV, et al. CES2 Expression in pancreatic adenocarcinoma is predictive of response to irinotecan and is associated with type 2 diabetes. JCO Precis Oncol. 2020;4:426–36. https://doi.org/10.1200/PO.19.00330 .
doi: 10.1200/PO.19.00330
Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science. 2020;368:973–80. https://doi.org/10.1126/science.aay9189 .
doi: 10.1126/science.aay9189
pubmed: 32467386
pmcid: 7757858
Gooiker GA, Lemmens VE, Besselink MG, et al. Impact of centralization of pancreati cancer surgery on resection rates and survival. Br J Surg. 2014;101(8):1000–5.
doi: 10.1002/bjs.9468
Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15(6):1651–60.
doi: 10.1245/s10434-008-9839-8
Cherny NI, Dafni U, Bogaerts J, et al. ESMO-magnitude of clinical benefit scale version 1.1. Ann Oncol. 2017;28(10):2340–66.
doi: 10.1093/annonc/mdx310
Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. European study group for pancreatic cancer. Lancet. 2017;389(10073):1011–24.
doi: 10.1016/S0140-6736(16)32409-6
Conroy T, Hammel P, Hebbar M, et al. Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406.
doi: 10.1056/NEJMoa1809775
Versteijne E, Suker M, Groothuis K, Dutch Pancreatic Cancer Group, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III preopanc trial. J Clin Oncol. 2020;38(16):1763–73.
doi: 10.1200/JCO.19.02274
Jang J, Han Y, Lee H, et al. Oncological benefit of neoadjuvant chemoradiotherapy with gemcitabine versus surgery in patients with borderline resectable pancreatic cancer. Ann Surg Treat Res. 2018;94(4):190–5.
doi: 10.4174/astr.2018.94.4.190
Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26:3496–502.
doi: 10.1200/JCO.2007.15.8634
Sohal D, Duong MT, Ahmad S, et al. SWOG S1505: results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). J Clin Oncol. 2020;38:4504 (suppl; abstr 4504).
doi: 10.1200/JCO.2020.38.15_suppl.4504
Evans DB, George B, Tsai S, et al. Non-metastatic pancreatic cancer: resectable, borderline resectable, and locally advanced-definitions of increasing importance for the optimal delivery of multidisciplinary therapy. Ann Surg Oncol. 2015;22:3409–13.
doi: 10.1245/s10434-015-4649-2
Hammel P, Huguet F, Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–53.
doi: 10.1001/jama.2016.4324
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
doi: 10.1056/NEJMoa1011923
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
doi: 10.1056/NEJMoa1304369
Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol. 2013;14:317–26.
doi: 10.1016/S1470-2045(13)70021-4
Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–57.
doi: 10.1016/S0140-6736(15)00986-1
Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–27.
doi: 10.1056/NEJMoa1903387
Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.
doi: 10.1126/science.aan6733
Maltoni M, Scarpi E, Dall’Agata M, et al. Systematic versus on-demand early palliative care: a randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life. Eur J Cancer. 2016;69:110–8. https://doi.org/10.1016/j.ejca.2016.10.004 .
doi: 10.1016/j.ejca.2016.10.004
pubmed: 27821313
Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev. 2011. https://doi.org/10.1002/14651858.CD007519.pub2 .
doi: 10.1002/14651858.CD007519.pub2
pubmed: 21412903
pmcid: 6464722
Levy MJ, Baron TH, Gostout CJ, et al. Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: an evidence-based approach. Clin Gastroenterol Hepatol. 2004;2(4):273–85.
doi: 10.1016/S1542-3565(04)00055-2
Roberts KJ, Bannister CA, Schrem H. Enzyme replacement improves survival among patients with pancreatic cancer: results of a population-based study. Pancreatology. 2019;19(1):114–21. https://doi.org/10.1016/j.pan.2018.10.010 .
doi: 10.1016/j.pan.2018.10.010
pubmed: 30385188
Informe SEOM. Las cifras del cáncer en España; 2019.
Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16:36–46.
doi: 10.1016/S1470-2045(14)71123-4
Bridgewater JA, Goodman KA, Kalyan A, Mulcahy MF. Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling. Am Soc Clin Oncol Educ Book. 2016;35:e194-203. https://doi.org/10.1200/EDBK_160831 (PMID: 27249723).
doi: 10.1200/EDBK_160831
pubmed: 27249723
Van Dyke AL, Langhamer MS, Zhu B, et al. Family history of cancer and risk of biliary tract cancers: results from the biliary tract cancers pooling project. Cancer Epidemiol Biomarkers Prev. 2018;27(3):348–51. https://doi.org/10.1158/1055-9965.EPI-17-1003 (Epub 2018 Jan 16 PMID: 29339358).
doi: 10.1158/1055-9965.EPI-17-1003
pubmed: 29339358
pmcid: 5835211
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–2128.
doi: 10.1016/j.jhep.2014.01.021
Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma: evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018;15(2):95–111.
doi: 10.1038/nrclinonc.2017.157
Furlan A, Ferris JV, Hosseinzadeh K, Borhani AA. Gallbladder carcinoma update: multimodality imaging evaluation, staging, and treatment options. AJR Am J Roentgenol. 2008;191:1440–7.
doi: 10.2214/AJR.07.3599
Sainani NI, Catalano OA, Holalkere NS, et al. Cholangiocarcinoma: current and novel imaging techniques. Radiographics. 2008;28:1263–87.
doi: 10.1148/rg.285075183
Haber PK, Sia D. Translating cancer genomics for precision oncology in biliary tract cancers. Discov Med. 2019;28(155):255–65.
pubmed: 32053766
Lamarca A, Barriuso J, McNamara M, Valle JW. Biliary tract cancer: state of the art and potential role of DNA damage. Cancer Treat Rev. 2018;70:166–77.
doi: 10.1016/j.ctrv.2018.09.002
Moncada S, Nervi B, Pinto M, Abou-Alfa G. Biliary tract cancer prognostic and predictive genomics. Chin Clin Oncol. 2019;8(4):42.
doi: 10.21037/cco.2019.07.06
Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–73.
doi: 10.1016/S1470-2045(18)30915-X
Ben-Josef E, Guthrie KA, El-Khoueiry AB, et al. SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol. 2015;20(33):2617–22.
doi: 10.1200/JCO.2014.60.2219
Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30(16):1934–40.
doi: 10.1200/JCO.2011.40.5381
Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
doi: 10.1056/NEJMoa0908721
Glimelius B, Hoffman K, Sjödén PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593–600.
doi: 10.1093/oxfordjournals.annonc.a010676
Sharma A, Dwary AD, Mohanti BK, et al. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study. J Clin Oncol. 2010;28:4581–6.
doi: 10.1200/JCO.2010.29.3605
Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96(6):896–902.
doi: 10.1038/sj.bjc.6603648
Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–74.
doi: 10.1038/sj.bjc.6605779
Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391–8.
doi: 10.1093/annonc/mdt540
Lamarca A, Palmer DH, Wasan HS, et al. ABC-06. A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients with locally advanced or metastatic biliary tract cancers previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. J Clin Oncol. 2019;37:4003–4003. https://doi.org/10.1200/JCO.2019.37.15_suppl.4003 .
doi: 10.1200/JCO.2019.37.15_suppl.4003
Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807. https://doi.org/10.1016/S1470-2045(20)30157-1 .
doi: 10.1016/S1470-2045(20)30157-1
pubmed: 32416072
pmcid: 7523268
Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84.
doi: 10.1016/S1470-2045(20)30109-1
Wainberg ZA, Lassen UN, Elez E, et al. Efficacy and safety of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated biliary tract cancer (BTC): A cohort of the ROAR basket trial. J Clin Oncol. 2019;37(4_suppl):187. https://doi.org/10.1200/JCO.2019.37.4_suppl.187 ((abstract 187)).
doi: 10.1200/JCO.2019.37.4_suppl.187
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.
doi: 10.1200/JCO.19.02105
Marabelle A, Fakih MG, Lopez J, et al. Association of tumor mutational burden with outcomes in patients with select advanced solid tumors treated with pembrolizumab in KEYNOTE-158. Ann Oncol. 2019;30:v475-532. https://doi.org/10.1093/annonc/mdz253 (suppl_5).
doi: 10.1093/annonc/mdz253
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–9.
doi: 10.1056/NEJMoa1714448
Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400–9.
doi: 10.1158/2159-8290.CD-16-1237